Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
Scheduled presentations at the 2018
Oral Presentation: SAKURA 1 and 2 Phase 3 Pivotal Studies
DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate
to Severe Glabellar Lines will be delivered during the Premier
Global Hot Topics session by
ePoster Presentation: Duration of Effect in Two Phase 3, Randomized,
Double-Blind, Placebo Controlled, Multi-Center Trials Evaluating Safety
& Efficacy of DaxibotulinumtoxinA for Injection Treating Moderate to
Severe Glabellar Lines (SAKURA 1 & 2). Dr.
"We are very pleased that the compelling data from our SAKURA trials
will be highlighted by key luminaries at a leading
About
"Revance Therapeutics" and the Revance logo are registered trademarks of
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to Revance Therapeutics' 2018 Financial Outlook and other financial performance, the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and statements about our ability to obtain regulatory approval; and potential benefits of our drug product candidates and our technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425006374/en/
INVESTORS
jherbert@revance.com
or
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source:
News Provided by Acquire Media